☆ 4.7 Review

Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies

FRONTIERS IN ENDOCRINOLOGY (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Cardiac & Cardiovascular Systems

The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer

Filipe Cirne et al.

Summary: The study suggests that GnRH antagonists, a relatively new class of drugs for androgen deprivation therapy in prostate cancer, may cause significantly fewer adverse cardiovascular effects than the more commonly used GnRH agonists, based on limited but consistent data.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

添加到收藏夹

Review Urology & Nephrology

Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials

Mohammad Abufaraj et al.

Summary: GnRH antagonists show better safety profiles in terms of overall mortality and cardiovascular events compared to agonists, but have higher rates of injection site reactions.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Oncology

Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study

Do Kyung Kim et al.

Summary: The study found that ADT may reduce the risk of ischemic cardiovascular diseases, cardiovascular intervention, and cerebrovascular diseases in patients with prostate cancer. The duration of ADT is associated with this risk reduction.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice

Patrick Davey et al.

Summary: This study analyzed real-world data from UK primary care setting and found that the GnRH antagonist degarelix had a significantly lower risk of cardiac events compared to GnRH agonists. Patients who received degarelix as first-line treatment switched treatment more frequently to GnRH agonists than those who initiated treatment with a GnRH agonist.

WORLD JOURNAL OF UROLOGY (2021)

添加到收藏夹

Article Oncology

Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases

Gincy George et al.

Summary: Observational studies have shown increased risk of acute myocardial infarction and arrhythmia for prostate cancer patients using GnRH antagonists compared to agonists, with no overall difference in risk of cardiovascular disease. Having a history of cardiovascular disease may modify the associations with certain subtypes of CVD. Further research is needed to address potential confounding factors.

INTERNATIONAL JOURNAL OF CANCER (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Ten-year cardiovascular risk among cancer survivors: The National Health and Nutrition Examination Survey

Xiaochen Zhang et al.

Summary: Data from the National Health and Nutrition Examination Survey show that adults with a history of self-reported cancer have a higher 10-year ASCVD risk, especially for specific cancer types. In addition, age is an effect modifier for the association between cancer history and elevated 10-year ASCVD risk.

PLOS ONE (2021)

添加到收藏夹

Article Medicine, General & Internal

Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer

Lova Sun et al.

Summary: The study found that there are significant gaps in the assessment and management of cardiovascular risk factors in prostate cancer patients initiating ADT, highlighting the need for interventions to improve this situation.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Association of Serum Testosterone and Luteinizing Hormone With Blood Pressure and Risk of Cardiovascular Disease in Middle-Aged and Elderly Men

Mengyuan Qu et al.

Summary: The study found that the decline in sex hormone levels due to aging may be an important factor in male aging and cardiovascular diseases. Testosterone levels were inversely associated with hypertension prevalence, but factors like age, weight, smoking, and family history can impact this association.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

添加到收藏夹

Article Health Care Sciences & Services

Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis

Valentina Perrone et al.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer

Celestia S. Higano

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Urology & Nephrology

Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease

David Margel et al.

JOURNAL OF UROLOGY (2019)

添加到收藏夹

Review Urology & Nephrology

Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies

Giovanni Corona et al.

JOURNAL OF SEXUAL MEDICINE (2018)

添加到收藏夹

Article Oncology

Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes

Marie C. Hupe et al.

FRONTIERS IN ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer

Alessandro Sciarra et al.

MEDICINE (2016)

添加到收藏夹

Review Urology & Nephrology

The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK

Derek J. Rosario et al.

WORLD JOURNAL OF UROLOGY (2016)

添加到收藏夹

Article Oncology

Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT

Laurence Klotz et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Review Endocrinology & Metabolism

Testosterone: a metabolic hormone in health and disease

Daniel M. Kelly et al.

JOURNAL OF ENDOCRINOLOGY (2013)

添加到收藏夹

Article Urology & Nephrology

Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?

Tom Pickles et al.

BJU INTERNATIONAL (2012)

添加到收藏夹

Review Urology & Nephrology

An update on the use of gonadotropinreleasing hormone antagonists in prostate cancer

Laurent Boccon-Gibod et al.

THERAPEUTIC ADVANCES IN UROLOGY (2011)

添加到收藏夹

Article Urology & Nephrology

Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy

Juan Morote et al.

BJU INTERNATIONAL (2009)

添加到收藏夹

Review Pharmacology & Pharmacy

Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer

P Mongiat-Artus et al.

EXPERT OPINION ON PHARMACOTHERAPY (2004)

添加到收藏夹

Article Urology & Nephrology

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

D McLeod et al.

UROLOGY (2001)

添加到收藏夹

Article Urology & Nephrology

Is the flare phenomenon clinically significant?

GJ Bubley

UROLOGY (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.